Trials / Terminated
TerminatedNCT02382549
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
A TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A HELPER PEPTIDE VACCINE PLUS COMBINATION OF BRAF INHIBITION AND MEK INHIBITION (MEL61)
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Craig L Slingluff, Jr · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood and tumor samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRAF inhibitor | BRAF inhibitor |
| BIOLOGICAL | 6MHP | 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides |
| DRUG | MEK inhibitor | MEK Inhibitor |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2015-03-06
- Last updated
- 2023-12-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02382549. Inclusion in this directory is not an endorsement.